Search Results

Kineta, Inc., a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced the completion of its reverse merger with Yumanity Therapeutics, Inc.

Yumanity Therapeutics, Inc. (“Yumanity” or the “Company”) (Nasdaq: YMTX) announced today that its Board of Directors has declared a special dividend in connection with the previously announced asset sale to Janssen Pharmaceutica NV.

Yumanity Therapeutics, Inc. today announced financial results for the third quarter ended September 30, 2022 and provided an overview of the Company’s recent corporate developments.

Yumanity Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced it has entered into definitive agreements for two strategic transactions.

Yumanity Therapeutics, Inc. announced the filing of a registration statement on Form S-4 with the U.S. Securities and Exchange Commission.

Yumanity Therapeutics, Inc. announced that the registration statement on Form S-4, relating to the previously announced asset sale to Janssen Pharmaceutica NV and merger with Kineta, Inc., has been declared effective by the U.S. Securities and Exchange Commission.

Yumanity Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced financial results for the second quarter ended June 30, 2022, and provided an overview of the Company’s recent corporate developments.

Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today provided an update on recent corporate developments.

Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2022, and provided an overview of the Company’s recent corporate developments.

Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, announced the grant to two employees of non-statutory stock options for the purchase of up to an aggregate of 6,000 shares of Yumanity’s common stock.